Distillate Capital Partners LLC Buys 9,129 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Distillate Capital Partners LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.6% during the third quarter, Holdings Channel reports. The institutional investor owned 37,112 shares of the biopharmaceutical company’s stock after purchasing an additional 9,129 shares during the quarter. Regeneron Pharmaceuticals comprises 1.1% of Distillate Capital Partners LLC’s holdings, making the stock its 26th biggest position. Distillate Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $20,876,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Caitlin John LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,274 shares of company stock worth $4,142,738 in the last three months. Company insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a report on Monday, February 9th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. HSBC raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $745.77 on Monday. The stock has a market capitalization of $78.84 billion, a price-to-earnings ratio of 17.94, a P/E/G ratio of 2.00 and a beta of 0.40. The firm’s 50-day moving average price is $769.73 and its two-hundred day moving average price is $695.68. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.07 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.